A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection.
BW A515U (6-Deoxyacyclovir) is a pro-drug of acyclovir and almost 100% is absorbed orally. 250 mg orally 6-hourly for 10 days was given to 4 hepatitis B surface antigen/e antigen-positive carriers. No consistent effect on productive viral replication, as determined by serum DNA polymerase and DNA levels was observed. The changes that occurred in these markers and transaminases in 1 patient were attributed to a spontaneous depression of productive viral replication.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy; D004279:DNA, Viral / Q000097:blood; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000502:physiology; D006716:Homosexuality; D006801:Humans; D008297:Male; D010865:Pilot Projects; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D004279:DNA, Viral; C041468:desciclovir; D004259:DNA-Directed DNA Polymerase; D000212:Acyclovir